Production of highly immunogenic virus-like particles of bovine papillomavirus type 6 in silkworm pupae
•BPV6-VLP were produced in silkworm pupae using a baculovirus expression system.•BPV6-VLP were affinity-purified by heparin column chromatography.•BPV6-VLP-immunized mice produced a specific IgG to BPV6.•BPV6-specific IgG recognized BPV6 antigen with high sensitivity in teat papilloma legion. Bovine...
Saved in:
Published in | Vaccine Vol. 35; no. 43; pp. 5878 - 5882 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
13.10.2017
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •BPV6-VLP were produced in silkworm pupae using a baculovirus expression system.•BPV6-VLP were affinity-purified by heparin column chromatography.•BPV6-VLP-immunized mice produced a specific IgG to BPV6.•BPV6-specific IgG recognized BPV6 antigen with high sensitivity in teat papilloma legion.
Bovine papillomaviruses (BPVs) are the causative agent of bovine teat papillomatosis, which can lead to severe economic losses in dairy cattle. Among the 14 identified BPV genotypes, BPV type 6 (BPV6) is the most frequently detected in teat papilloma lesions, and is therefore thought to play a major role in teat papillomatosis. To develop an effective vaccine against BPV6 infection, we produced virus-like particles of BPV6 (BPV6-VLP) in silkworm (Bombyx mori) pupae and purified these by heparin affinity chromatography using a single column. About 0.7mg purified BPV6-VLP was obtained from one pupa. BPV6-VLP-immunized mice produced a specific IgG to BPV6 that recognized BPV6 antigen with high sensitivity in an immunohistochemical analysis. Thus, silkworm pupae are a useful bioreactor for the production of BPV6-VLP, which can potentially be used as a vaccine for bovine teat papillomatosis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2017.08.079 |